Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reduce Warning Letter Threshold In Draft CPG, HIMA Advises FDA

This article was originally published in The Gray Sheet

Executive Summary

FDA inspectors should not consider the failure of a manufacturer to meet a single inspectional objective or part of an inspectional objective as a major deficiency worthy of a warning letter, the Health Industry Manufacturers Association recommends in comments on FDA's draft compliance program guidance.
Advertisement

Related Content

"Minor" Infractions Will Not Trigger Warning Letter Under Final CPG
"Minor" Infractions Will Not Trigger Warning Letter Under Final CPG
FDA Considering Alternatives To Abbreviated Inspections As QSIT Gears Up
Abbreviated FDA Inspections Outlined In Draft CPG For Auditing Program
Abbreviated FDA Inspections Outlined In Draft CPG For Auditing Program
QSIT Validation Study Shows Promise Of New Inspection Technique - FDA
Advertisement
UsernamePublicRestriction

Register

MT012584

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel